Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S204000
Reexamination Certificate
active
07041690
ABSTRACT:
The present invention provides compounds of Formula I, compositions and methods that are useful for treating viral infections and associated diseases, particularly HCV infections and associated diseases
REFERENCES:
patent: WO 96/35953 (1996-05-01), None
patent: WO 09833501 (1998-01-01), None
patent: WO 00/06529 (1999-07-01), None
patent: WO 00/10573 (1999-08-01), None
patent: WO 01/58853 (2001-02-01), None
patent: WO 0177091 (2001-04-01), None
patent: WO 02/04425 (2001-07-01), None
Vranicar et al(2002): STN International CAPLUS database, Columbus (Ohio), Accession No., 2002:288632.
XP-002260066 “Analogs of biologically active compounds. V. Synthesis and oxidative decarboxylation of 1-pheny1-3-(4-chlorophenyl)-4-pyrazolylpyruvic acid”, Acta Universitatis Palackianae Olomucensis, Fucultas rerum Naturalium, 1990, vol. 97, No. Chem. 29, pp 145-50.
XP-002260067 “The structure of .beta-heteroaryl-.alpha., .beta.-dehydro-alpha.-amino acid derivatives, intermediates in the synthesis of fused pyran-2-ones. Substituted methyl (Z)-benzoylamino-3-(5-oxopyrazoliny-4) propenoates.”, J Heterocyclic Chem., , 1991, vol. 28, No. 8, pp 1961-4.
XP-002260068 “Synthesis of 3-methyl-1-phenyl-and 1, 3-diphenyl-5-oxo-, DELTA.2-pyrazoline-4-methylene derivatives”, Ind J Chem., Sect. B. 1983, vol. 228, No. 7, pp 637-9.
XP002260069 “Determination of acids and their strength in isobutyl methyl ketone.”, Coll. Czech. Chem. Comm., 1982, vol. 47, No. 4, pp 1203-15.
XP002260070 “reactions of 4-′(1,3-diphenyl-4-pyrazolyl) methtlene!-2-phenyl-2-oxazolin-5-one with Grignard reagents and diazoalkanes”,J. Prakt. Chem., 1974, vol. 316, No. 3, pp 363-8.
XP-002260071 “Chemical reaction of 4-‘4’-(1′, 3′-diphenylpyrazolyl) methylene!-2-phenyl-5-oxo(4H)-1, 3-thiazole”,Act. Chim. Acad, Sci. Hungar, 1974, vol. 80, No. 1, pp 119-23.
XP-002260065 J. of the Chem Soc, Perkin Trans 1(2002) , vol. 5, 2002, pp 675-681.
XP-004150869 Tetrahedron vol. 55, No. 1, 1999, pp 271-278.
XP-002190259 “Practice of Medicinal Chemistry”,Practice of Medicinal Chemistry, 1996, pp 203-237.
Kato et al. Proc. Natl. Acad. Sci. USA (1990), 87; 9524-9528.
Van Doorn, L.J., J. of Medical Virology (1994), 43, 345-356.
Lau, J.Y. et al., J Infect Dis. (1995), 171(2), 281-9.
Behrens et al. EMBO J (1996) 15: 12-22.
Houghton, M., Hepatitis C viruses Fields Virology: (1996), Third Edition, edited by B.N. Fields, D.M. Knoip e, P.M. Howley, et al, Lippincott-Raven Publishers, Philadelphia, pp 1035-1058.
Lohmann et al. (1997) J Viro. 71: 8416-8428.
Ishido et al, Biochem. Biophys. Res. Comm. (1998), 244: 35-40.
Ferrari, E., et at., J.Virol. (1999), 73: 1649-1654.
Webster, G., et al. Balliere's Clinical Gastroenterology (2000), 14, 229-240.
Finzel Barry Craig
Gao Hua
Greene Meredith L.
Gross Rebecca J.
Nugent Richard Allen
Pharmacia & Upjohn Company LLC
Shameem Golam M. M.
Tidwell Jeffrey H.
Zielinski Bryan C.
LandOfFree
Inhibitors of HCV NS5B polymerase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of HCV NS5B polymerase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of HCV NS5B polymerase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3572594